A statement needs its source
What supports the claim?
Examine eight claims without turning them into a product ranking. Each open record separates the claim from its source, preserves the missing answer and gives a question to take to the responsible professional or company.
The claims below are propositions being examined, not publication findings.
These fixed records provide source context, not diagnosis, product authentication, photograph assessment, ingredient compatibility or a decision to start, stop or change treatment. No health or label information is entered here. Ordinary website support does not replace qualified medical care.
A similar name is not the same product
Claim to examine
A review of a product called Clear describes the hydroquinone preparation I am comparing.
What the record supports
Obagi’s current Nu-Derm Clear prescription page identifies hydroquinone 4% cream. Its separate Clear Fx page describes an arbutin-based brightening cream and publishes its own price and customer reviews. The complete name and ingredient record distinguish these offerings.
Limit to retain
A shared brand or similar URL does not transfer a price, testimonial, ingredient or prescription requirement between products. This publication has not inspected a supplied item and cannot authenticate it or establish personal suitability from a public description.
A question to take forward
Which exact product name and preparation appear in the proposed quote or prescription, and which public claims actually refer to that same product?
Read the source in its own words
Obagi Nu-Derm Clear prescription creamObagi Nu-Derm Clear Fx Skin Brightening CreamA starting price must identify its offer
Claim to examine
The lowest monthly amount on the Spot On page is a verified plan price.
What the record supports
Spot On’s current plan cards show three months at $165 total with $54.99 monthly wording, and one month at $70 with $69.99 monthly wording. A different section describing Spot On itself states a starting price of $42 monthly. The product page displays a $54.99 starting amount.
Limit to retain
The inspected cards do not establish a corresponding $42 option or explain the discrepancy. A monthly display does not prove installment billing, physical quantity or a personal all-in charge. Neither the price nor the purchased period establishes a treatment course or better clinical result.
A question to take forward
Can the seller confirm the exact preparation, supplied amount, total charge and applicable billing terms in writing, and explain which starting-price statement applies to the proposed order?
A customer account is not causal evidence
Claim to examine
A favorable testimonial shows that the cream caused the change and that other readers can expect the same result.
What the record supports
FTC guidance distinguishes genuine personal experiences from evidence establishing a health product’s effects. It also explains that a generic results-vary disclaimer does not alone remove the typical-result impression of an exceptional-results endorsement. Spot On describes its published accounts as unsolicited and edited for clarity; that is the company’s attribution.
Limit to retain
No reviewer’s identity, full treatment history or outcome has been independently verified here. Incomplete causal evidence is not proof that an account is fabricated or that no improvement occurred. A public story, rating or photograph does not establish a typical result, adverse-effect rate or diagnosis.
A question to take forward
What evidence beyond the customer account addresses this exact preparation and claimed result, and which parts of that evidence are relevant to the clinical question under discussion?
An active name needs its formula and claim
Claim to examine
Products using the same brightening language have interchangeable ingredients, approval or evidence.
What the record supports
Spot On advertises hydroquinone, kojic acid and niacinamide in a compounded cream. Clear Fx’s record instead names arbutin. FDA explains that intended use and claims matter to product category, and that compounded medicines are not FDA-approved. Its hydroquinone communication identifies the specific approved medicine TRI-LUMA.
Limit to retain
These records do not support an ingredient conversion, strength ranking, personal combination or approval transfer. Evidence about one ingredient or finished medicine may not answer the claim made for another preparation. Retail cosmetic presentation alone is not a product-specific FDA classification or clearance decision.
A question to take forward
What is the complete proposed preparation, what claim is being made for it, and how closely does the cited evidence match that product and the concern being assessed?
Read the source in its own words
CoreAge Rx Spot On product pageCoreAge Rx Spot On public offerObagi Nu-Derm Clear Fx Skin Brightening CreamFDA: Is it a cosmetic, a drug, or both?FDA: Compounding and the FDA — Questions and AnswersFDA: Potentially harmful OTC skin-lightening productsA powder statement does not specify the whole ampoule
Claim to examine
The one-hundred-percent glutathione powder label establishes the concentration of the finished numbuzin ampoule.
What the record supports
The official declaration separates a glutathione powder entry from a longer ingredient list. The purity wording belongs to that component, while the complete product also lists other materials.
Limit to retain
The finished glutathione and TXA amounts are not established by the powder entry. No assay or independently appraised finished-product outcome is provided by this review.
A question to take forward
What exact concentration is stated for the supplied finished preparation, and which part of the product does each percentage describe?
Read the source in its own words
No.5 Glutathione TXA Advanced Dark Spot Ampoule ConcentrateHelp & FAQ | numbuzinAn ingredient amount does not measure a result
Claim to examine
Dr. Melaxin’s 20,000 ppm niacinamide statement establishes a degree of dark-spot improvement.
What the record supports
On the same measurement basis, 20,000 ppm equals 2%. The declared concentration identifies an ingredient amount, while the complete cream also includes fragrance and other constituents.
Limit to retain
The conversion does not establish a clinical outcome, comparative benefit or individual tolerance. The checked public record did not supply a complete controlled finished-cream report for independent appraisal.
A question to take forward
Which finished formula was tested, what outcome was measured and what evidence connects the advertised result to this exact cream?
Read the source in its own words
Niacinamide Picotonic Shot Pigmentation Cream – Dr.Melaxin.usShipping & Return – Dr.Melaxin.usA laboratory multiplier is not a human product comparison
Claim to examine
Caudalie’s 62-times vitamin C wording shows that Vinoperfect removes human dark spots 62 times better than a vitamin C serum.
What the record supports
The manufacturer attaches the comparison to an in-vitro tyrosinase-inhibition test involving viniferine. Its separately described human groups and scoring periods concern different evidence.
Limit to retain
The laboratory endpoint does not establish a head-to-head human comparison between finished retail serums. Complete reports were not independently appraised here.
A question to take forward
Which preparation, comparator and endpoint produced the multiplier, and what human evidence supports the specific appearance claim of interest?
A fruit-water percentage is not pure vitamin C
Claim to examine
The EQQUALBERRY Original serum’s forty-percent acerola statement means forty percent pure vitamin C.
What the record supports
The declaration names acerola fruit water at 400,000 ppm and separately lists a vitamin C derivative. It also declares niacinamide at 40,000 ppm.
Limit to retain
The fruit-water amount does not establish the amount of isolated vitamin C. Illustrative result images are not independently verified participant photographs.
A question to take forward
What material does each percentage name, and what complete study methods support the finished-serum result being advertised?